(NUVB) Nuvation Bio - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NYSE (USA) | Market Cap: 1.678m USD | Total Return: 91.2% in 12m
Avg Turnover: 19.4M
Qual. Beats: 1
Qual. Beats: 9
Warnings
Interest Coverage Ratio -10.5 is critical
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -1.10 < 1.0 - financial distress zone
Choppy
Tailwinds
Pead
Nuvation Bio Inc. (NUVB) is a clinical-stage biopharmaceutical company headquartered in New York, specializing in the development of targeted oncology therapies. The company’s pipeline is led by IBTROZI (taletrectinib), a ROS1 inhibitor currently positioned for the treatment of ROS1-positive non-small cell lung cancer. Additionally, the firm is advancing Safusidenib into Phase 3 clinical trials for the maintenance treatment of high-grade IDH1-mutant astrocytoma.
Operating within the biotechnology sector, Nuvation Bio utilizes a business model centered on high-risk, high-reward research and development, where value is primarily driven by clinical trial milestones and regulatory approvals rather than immediate revenue. The oncology market is characterized by intense competition and a rigorous FDA approval process that requires extensive safety and efficacy data across multiple trial phases.
Investors should review the comprehensive financial metrics and trend analysis available on ValueRay to better understand the companys valuation. This data-driven approach is essential for assessing a clinical-stage entity that lacks commercialized products and relies on capital markets to fund ongoing research operations.
- Taletrectinib clinical data and FDA approval timeline drive near-term valuation
- Safusidenib Phase 3 trial results determine long-term expansion into glioma market
- Cash runway and R&D burn rate dictate future equity financing needs
- Competitive landscape for ROS1 inhibitors impacts projected market share for Taletrectinib
- Regulatory milestones for IDH1-mutant astrocytoma treatment influence institutional investor confidence
| Net Income: -146.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 125.6 > 1.0 |
| NWC/Revenue: 357.9% < 20% (prev 3.86k%; Δ -3.50k% < -1%) |
| CFO/TA -0.21 > 3% & CFO -125.7m > Net Income -146.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (377.5m) vs 12m ago 11.49% < -2% |
| Gross Margin: 91.64% > 18% (prev 16.29%; Δ 75.35% > 0.5%) |
| Asset Turnover: 25.94% > 50% (prev 2.22%; Δ 23.72% > 0%) |
| Interest Coverage Ratio: -10.50 > 6 (EBIT TTM -150.2m / Interest Expense TTM 14.3m) |
| A: 0.84 (Total Current Assets 591.5m - Total Current Liabilities 79.5m) / Total Assets 610.2m |
| B: -1.82 (Retained Earnings -1.11b / Total Assets 610.2m) |
| C: -0.27 (EBIT TTM -150.2m / Avg Total Assets 551.4m) |
| D: 1.10 (Book Value of Equity 319.6m / Total Liabilities 290.7m) |
| Altman-Z'' = -1.10 = CCC |
| DSRI: 0.36 (Receivables 26.0m/5.46m, Revenue 143.0m/11.0m) |
| GMI: 0.18 (GM 16.29% / 91.64%) |
| AQI: 1.07 (AQ_t 0.02 / AQ_t-1 0.02) |
| SGI: 13.06 (Revenue 143.0m / 11.0m) |
| TATA: -0.03 (NI -146.0m - CFO -125.7m) / TA 610.2m) |
| Beneish M = 4.39 (Cap -4..+1) = D |
As of June 09, 2026, the stock is trading at USD 4.80 with a total of 2,963,936 shares traded.
Over the past week, the price has changed by -3.23%,
over one month by +0.21%,
over three months by +1.48% and
over the past year by +91.24%.
Nuvation Bio has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy NUVB.
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.3 | 156.9% |
P/S = 11.7328
P/B = 5.6333
Revenue TTM = 143.0m USD
EBIT TTM = -150.2m USD
EBITDA TTM = -148.2m USD
Long Term Debt = 47.3m USD (from longTermDebt, last quarter)
Short Term Debt = 7.63m USD (from shortTermDebt, last quarter)
Debt = 59.0m USD (corrected: LT Debt 47.3m + ST Debt 7.63m) + Leases 4.04m
Net Debt = -270.4m USD (calculated: Debt 59.0m - CCE 329.4m)
Enterprise Value = 1.41b USD (1.68b + Debt 59.0m - CCE 329.4m)
Interest Coverage Ratio = -10.50 (Ebit TTM -150.2m / Interest Expense TTM 14.3m)
EV/FCF = 23.58x (Enterprise Value 1.41b / FCF TTM 59.7m)
FCF Yield = 4.24% (FCF TTM 59.7m / Enterprise Value 1.41b)
FCF Margin = 41.74% (FCF TTM 59.7m / Revenue TTM 143.0m)
Net Margin = -102.1% (Net Income TTM -146.0m / Revenue TTM 143.0m)
Gross Margin = 91.64% ((Revenue TTM 143.0m - Cost of Revenue TTM 12.0m) / Revenue TTM)
Gross Margin QoQ = 93.25% (prev none%)
Tobins Q-Ratio = 2.31 (Enterprise Value 1.41b / Total Assets 610.2m)
Interest Expense / Debt = 24.25% (Interest Expense 14.3m / Debt 59.0m)
Taxrate = 0.0% (0.0 / 5.40m)
NOPAT = -150.2m (EBIT -150.2m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 5.80 (Total Current Assets 591.5m / Total Current Liabilities 102.0m)
Debt / Equity = 0.18 (Debt 59.0m / totalStockholderEquity, last quarter 319.6m)
Debt / EBITDA = 1.82 (negative EBITDA) (Net Debt -270.4m / EBITDA -148.2m)
Debt / FCF = -4.53 (Net Debt -270.4m / FCF TTM 59.7m)
Total Stockholder Equity = 331.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.48% (Net Income -146.0m / Total Assets 610.2m)
RoE = -44.10% (Net Income TTM -146.0m / Total Stockholder Equity 331.0m)
RoCE = -39.69% (EBIT -150.2m / Capital Employed (Equity 331.0m + L.T.Debt 47.3m))
RoIC = -28.27% (negative operating profit) (NOPAT -150.2m / Invested Capital 531.2m)
WACC = 10.61% (E(1.68b)/V(1.74b) * Re(10.13%) + D(59.0m)/V(1.74b) * Rd(24.25%) * (1-Tc(0.0)))
Discount Rate = 10.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 27.41%
[DCF] Terminal Value 67.94% ; FCFF base≈59.7m ; Y1≈60.0m ; Y5≈63.5m
[DCF] Fair Price = 2.83 (EV 713.6m - Net Debt -270.4m = Equity 984.0m / Shares 347.2m; r=10.61% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.29 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 4.0 | # QB: 9
EPS current Quarter (2026-06-30): EPS=-0.12 | Chg30d=-9.09% | Revisions=-20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.11 | Chg30d=-22.22% | Revisions=-20% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.28 | Chg30d=-27.27% | Revisions=-20% | GrowthEPS=+43.3% | GrowthRev=+222.1%
EPS next Year (2027-12-31): EPS=-0.06 | Chg30d=+58.62% | Revisions=-20% | GrowthEPS=+78.6% | GrowthRev=+43.3%